Vyne Therapeutics Inc - VYNE STOCK NEWS

VYNE Therapeutics has announced promising preclinical data on its novel pan-BET inhibitor, VYN201, for treating idiopathic pulmonary fibrosis (IPF). VYN201 demonstrated significant reductions in lung fibrosis and hydroxyproline levels compared to placebo. Specifically, at doses of 0.5 mg/ml and 1 mg/ml, VYN201 achieved a 65.8% reduction in lung fibrosis scores and an 8.8% improvement in blood oxygen saturation. The treatment also led to a 51.8% increase in functional lung volume. These results support the potential broad utility of VYN201 as a locally-administered anti-inflammatory and anti-fibrotic therapy. VYNE is currently evaluating VYN201 in a Phase 1b study for non-segmental vitiligo, seeking to further validate its safety and efficacy.

VYNE Therapeutics announced positive results from the Phase 1a trial of its investigational BET inhibitor, VYN201, designed for topical administration. Key findings reveal no quantifiable plasma concentrations of VYN201, which supports its 'soft' drug approach. Furthermore, all hematological parameters, including platelet counts, remained within normal ranges, a significant improvement compared to systemically administered BET inhibitors. The trial enrolled 30 healthy volunteers and demonstrated no serious adverse events. The Phase 1b results, focusing on patients with nonsegmental vitiligo, are expected in mid-2023, potentially marking a new treatment avenue in this therapeutic area.

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced participation in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference on March 30, 2023. CEO David Domzalski and Chief Scientific Officer Dr. Iain Stuart will engage in a fireside chat at 3:30 PM ET. Investors can also schedule 1-on-1 meetings during the event. The discussion will cover the company’s innovative therapies for immuno-inflammatory conditions, including their lead programs, VYN201 and VYN202. A replay of the webcast will be available on the company's website for 90 days post-conference. For details, visit vynetherapeutics.com.

VYNE Therapeutics reported progress in the clinical development of VYN201, a pan-BD BET inhibitor, for treating vitiligo. The Phase 1b trial is underway, with topline data anticipated in mid-2023. Preliminary Phase 1a results indicated no serious adverse events, allowing dose selection for the trial. VYNE's 2022 financial results showed a net loss of $23.2 million, significantly down from $73.3 million in 2021. Revenue declined to $0.5 million from $0.9 million. The company had $31.0 million in cash as of December 31, 2022, sufficient to fund operations into Q4 2023.

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced on February 28, 2023, that it has regained compliance with Nasdaq's minimum bid price requirement. The company received a Notification Letter indicating that its common stock's closing bid price was at $1.00 per share or greater for the last 10 consecutive business days, from February 13 to February 27, 2023. VYNE is focused on developing innovative therapies for immuno-inflammatory conditions, utilizing its proprietary bromodomain & extra-terminal (BET) domain platform, which includes lead programs VYN201 and VYN202.

VYNE Therapeutics Inc. (Nasdaq: VYNE), a clinical-stage biopharmaceutical company, announced that CEO David Domzalski will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference on March 7, 2023. The event will take place at 2:10 PM ET at the Boston Marriott Copley Place, where management will also hold 1-on-1 meetings with investors. A webcast link is provided for attendees to view the session online. The webcast replay will be accessible for 90 days post-conference. VYNE is focused on developing therapies for immuno-inflammatory conditions through its proprietary bromodomain & extra-terminal (BET) domain platform.

VYNE Therapeutics announced positive results from the Phase 1a trial of VYN201, a novel BET inhibitor for treating vitiligo. The study involved 30 healthy volunteers who received topically applied doses without any serious adverse events, confirming safety and tolerability. Key findings include no clinically relevant treatment emergent adverse events and no withdrawals from the trial. VYNE plans to evaluate selected doses in the ongoing Phase 1b trial involving non-segmental vitiligo patients, with results expected in mid-2023. The company aims to advance its BET inhibitor program as a differentiated therapy with promising efficacy and safety.